← Back to Clinical Trials
Recruiting NCT07635641

NCT07635641 REPROton-HN: Prospective Observational Study on Proton Re-irradiation for Locoregional Recurrences of Head and Neck Tumors

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07635641
Status Recruiting
Phase
Sponsor Istituto Clinico Humanitas
Condition Head & Neck Cancer
Study Type OBSERVATIONAL
Enrollment 50 participants
Start Date 2026-05-29
Primary Completion 2031-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 50 participants in total. It began in 2026-05-29 with a primary completion date of 2031-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Some patients with head and neck cancer may develop a tumor recurrence in an area that has already been treated with radiotherapy. In these situations, surgery is not always possible, and giving radiotherapy again can be challenging because nearby healthy tissues and organs may already have received high radiation doses. The REPROton-HN study is evaluating the use of proton therapy for these patients. Proton therapy is a type of radiation treatment that can deliver radiation more precisely to the tumor while reducing exposure to surrounding healthy tissues. The aim of the study is to better understand how safe and effective proton therapy is when used as a second course of radiation treatment. Researchers will monitor side effects, tumor control, survival, and patients' quality of life. The results may help improve treatment planning and identify which patients are most likely to benefit from proton therapy in the future.

Eligibility Criteria

Inclusion Criteria: * ≥ 18 years old * ECOG 0-2 * Pathologically and or radiologically confirmed head and neck cancer recurrence * Indication for proton therapy * Written informed consent for REPRO-HN according to applicable legal and ethical requirements by the end of radiotherapy treatment Exclusion Criteria: * Age \< 18 years old * ECOG\>3 * Life expectancy \< 3 months * Inability to provide informed consent

Contact & Investigator

Central Contact

Maria Ausilia Teriaca, MD, radiation oncologist

✉ maria.ausilia.teriaca@cancercenter.humanitas.it

📞 +39 0282247461

Principal Investigator

Maria Ausilia Teriaca, MD, radiation oncologist

PRINCIPAL INVESTIGATOR

Humanitas Research Hospital IRCCS, Rozzano-Milan

Frequently Asked Questions

Who can join the NCT07635641 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Head & Neck Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07635641 currently recruiting?

Yes, NCT07635641 is actively recruiting participants. Contact the research team at maria.ausilia.teriaca@cancercenter.humanitas.it for enrollment information.

Where is the NCT07635641 trial being conducted?

This trial is being conducted at Rozzano, Italy.

Who is sponsoring the NCT07635641 clinical trial?

NCT07635641 is sponsored by Istituto Clinico Humanitas. The principal investigator is Maria Ausilia Teriaca, MD, radiation oncologist at Humanitas Research Hospital IRCCS, Rozzano-Milan. The trial plans to enroll 50 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology